Dongyin Chen

Dongyin Chen

Auto-generated profile, based on publicly available information

Dongyin Chen

Medical Basic Research Innovation Center for Cardiovascular and Cerebrovascular Diseases, Ministry of Education, International Joint Laboratory for Drug Target of Critical Illnesses, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YZYu Zhang
Yu Zhang
YLYingchun Li
Yingchun Li
XCXiang Chen
Xiang Chen
XCXuan Chen
Xuan Chen
CCChao Chen
Chao Chen
DCDongyin Chen
Dongyin Chen

1 February 2014 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
LZLiying Zhang
Liying Zhang
XJXiaojian Jia
Xiaojian Jia
JDJizhe Dong
Jizhe Dong
DCDongyin Chen
Dongyin Chen
Jun-Ping LiuJun-Ping Liu
Jun-Ping Liu
XWXiaoan Wen
Xiaoan Wen

23 February 2017 in Synthesis
Verified
Journal Article
Closed access
PDF file
LYLei Yang
Lei Yang
HLHonghua Luo
Honghua Luo
YSYan Sun
Yan Sun
ZSZhenyu Shi
Zhenyu Shi
KNKaidong Ni
Kaidong Ni
DCDongyin Chen
Dongyin Chen
A highly efficient copper-catalyzed one-pot protocol is developed for the synthesis of 4-aminoquinazolines from easily available 2-iodo- or 2-bromobenzimidamides, aldehydes, and sodium azide. This one-pot approach proceeds via consecutive copper-catalyzed SNAr substitution, reduction, cyclization, oxidation and tautomerization. The corresponding target products (26 examples) are obtained in 50–90% yield.

13 October 2017 in Archiv der Pharmazie
Verified
Journal Article
Closed access
PDF file
DCDongyin Chen
Dongyin Chen
FXFengguo Xu
Fengguo Xu
PZPu Zhang
Pu Zhang
JDJie Deng
Jie Deng
HSHongbin Sun
Hongbin Sun
JLJun Liu
Jun Liu

1 January 2020 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CCChao Chen
Chao Chen
RSRenhua Sun
Renhua Sun
YSYan Sun
Yan Sun
XCXuan Chen
Xuan Chen
FLFei Li
Fei Li
DCDongyin Chen
Dongyin Chen

1 January 2021 in Journal of Cancer
Verified
Journal Article
Open access
YZYi Zhang
Yi Zhang
JCJunjie Chen
Junjie Chen
ZCZhen Che
Zhen Che
CSChuanjun Shu
Chuanjun Shu
DCDongyin Chen
Dongyin Chen
JZJianwei Zhou
Jianwei Zhou
Background: Cisplatin (DDP) is a highly effective chemotherapeutic agent to most solid tumors including gastric cancer (GC), however, its clinical value is limited due to severe toxic side effects and secondary drug resistance. JP3, a JWA protein based MMP2-targeted polypeptide, known to inhibit the growth of GC in vivo. However, the bidirectional effects of JP3 in DDP-resistant GC and normal cells have not been demonstrated. The present study aims to investigate the actions of JP3 on protecting normal cells from the toxicity of DDP while enhancing its anti-tumor effects on GC cells.